Current status and future perspectives of bispecific antibodies in the treatment of lung cancer

作     者：Wanying Wang Tianyu Qiu Fei Li Shengxiang Ren 

作者机构：Department of Medical OncologyShanghai Pulmonary Hospital and Institute of Thoracic CancerSchool of MedicineTongji UniversityShanghai 200433China Department of PathologySchool of Basic Medical SciencesFudan UniversityShanghai 200032China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2023年第136卷第4期

页      面：379-393页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：sponsored by grants from the National Natural Science Foundation of China(Nos.82172869 and 81972167) the Program of Shanghai Academic Research Leader(No.21XD1423200) the program of Shanghai Shenkang Hospital Development Center(No.SHDC12019133). 

主　　题：Bispecific antibodies Lung cancer Immunotherapy Targeted therapy 

摘      要：Monoclonal antibodies have been successfully incorporated into the current therapeutical landscape of lung cancer in the last decades.Recently,with technological advances,bispecific antibodies(bsAbs)have also shown robust efficacy in the treatment of malignant cancers,including lung cancer.These antibodies target two independent epitopes or antigens and have been extensively explored in translational and clinical studies in lung cancer.Here,we outline the mechanisms of action of bsAbs,related clinical data,ongoing clinical trials,and potent novel compounds of various types of bsAbs in clinical studies,especially in lung cancer.We also propose future directions for the clinical development of bsAbs,which might bring a new era of treatment for patients with lung cancer.